As it plows ahead in its efforts to secure an FDA greenlight for its light- and sound-based neuromodulation device to treat Alzheimer’s disease, Cognito Therapeutics is taking an even closer look at ...
New drugs for Alzheimer’s are finally coming onto the market after decades of failed attempts to slow its devastating progression. But startup Cognito Therapeutics is taking a drug-free approach to ...
Cognito Therapeutics has spent the better part of the last decade developing neuromodulation technology that it claims could stop and even reverse the progression of Alzheimer’s and other ...
Just as a new wave of approved drugs for Alzheimer’s disease reaches patients, medical device company Cognito Therapeutics has raised a fresh $35 million to advance its alternative treatment for the ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a late-stage developer of disease-modifying therapies to treat neurodegenerative disorders, announced today continued active treatment in the ...
- Continued active treatment in the OVERTURE II OLE study demonstrated durability and preservation of brain structure and volume via MRI measurements over 18 months - Spectris™ treatment was well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback